TY  - CONF

T1  - Adjusting for treatment crossover in the BREAK-3 metastatic melanoma trial for dabrafenib: Preliminary analysis

JO  - JOURNAL OF CLINICAL ONCOLOGY

PY  - 2013/05/20

AU  - Latimer N

AU  - Abrams KR

AU  - Amonkar M

AU  - Stapelkamp C

AU  - Swann RS

ED  - 

VL  - 31

IS  - 15

Y2  - 2024/12/21

ER  -